Related Experiment Video

Updated: Sep 22, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

725

Emerging mechanisms of immunotherapy resistance in sarcomas

Vaia Florou1, Breelyn A Wilky2

  • 1Department of Medicine, Huntsman Cancer Institute at University of Utah, Salt Lake City, UT 84112, USA.

Cancer Drug Resistance (Alhambra, Calif.)
|May 18, 2022
PubMed

Insights

Most sarcoma patients do not respond to immune therapies due to low tumor immunogenicity. Future trials aim to boost immune responses and explore cellular therapies for better outcomes in sarcoma treatment.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Sarcomas are rare mesenchymal tumors with poor prognosis in advanced stages.
  • Traditional chemotherapies have limited efficacy in metastatic and refractory sarcomas.
  • While some sarcomas respond to immune therapies, most patients exhibit resistance.

Purpose of the Study:

  • To review emerging data on resistance mechanisms to immune checkpoint inhibitors in sarcoma.
  • To discuss biomarkers for immune therapy response in sarcoma clinical trials.
  • To explore future therapeutic strategies for enhancing sarcoma immunogenicity and efficacy of immunotherapies.

Main Methods:

  • Review of genetic and transcriptomic datasets.
  • Analysis of clinical trial data for immune therapies in sarcoma.
  • Exploration of biomarkers associated with treatment resistance and response.

Main Results:

  • Low expression of immune-related genes correlates with resistance to checkpoint inhibitor monotherapy.
  • Sarcoma resistance may stem from insufficient tumor immunogenicity.
  • Biomarkers are being explored to predict response to immune therapy.

Conclusions:

  • Enhancing tumor immunogenicity is crucial for improving checkpoint inhibitor efficacy in sarcoma.
  • Adoptive cellular therapies offer potential to overcome antigen presentation deficiencies.
  • Further research is needed to develop effective immune-based treatments for sarcoma.
Keywords:
Sarcomachemotherapyclinical trialsimmune resistanceimmune therapyimmunogenicity

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

19.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
681
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K